Wednesday, March 1, 2017

GRAIL Raises $900M For Cancer Detection Efforts

Menlo Park-based GRAIL, announced this morning that it has raised $900M in a first close of a planned, $1 billion funding round. The Series B funding was led by Arch Venture Partners, and included Johnson and Johnson Innovation, Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. GRAIL is a spinout of life sciences equipment maker Illumina, which spun the startup out in January of last year.